AFFY will come back to market, irrespective what Bashers fear mongering,here is why!
The reaction when promptly treated will prevent life threatening.
Sub-cutaneous administration will prevent sudden reaction, hence the first day administration can be administered this way.
A simple test will determine whether the patients are prone to this reaction.
It is not huge, Takeda can overcome these adversaries with their action plan and enforcing stricter administrative procedures.
For all those affected, it looks FMS did not take prompt action to provide the affected patients the necessary relief. Whether they did purposely to help the competitor is a billion $ question, is GWP is part of this gang , I won't rule out!
It is JUST FIRST DAY REACTION! For all those shorties, remember just this WORD only FIRST DAY REACTION once it is taken care of, life long the patients can be administered with Peganesatide without any additional precautions.
Clearly AMGNS hand through FMS is visible to take out to destroy the competitor.
Dr. Daniel W. Coyne, a kidney specialist at Washington University in St. Louis, in a NY Times article recognizes that “two in 10,000 deaths on first exposure is unacceptable, compared to nothing like this” with industry standard medications. Under the O recall cirmcumstances, Dr. Ajay K. Singh, a kidney specialist at Brigham and Women’s Hospital in Boston, in a NY Times article cautions "it might be hard for Affymax and Takeda to show [to the FDA] the safety of their drug without a huge study."